Gossamer Bio, Inc.
- Last sale
- Nov 12, 2026 · -4.39%
- Market cap
- $67.95M
- 6.12M shares
- Filings
- 490
Q3 2026−57.7% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−18.1% FY25 yoy
- $67.95M
- —
- 0.9×
- —
- -229.63%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $48,471,000 | reported | |
| FY 2024 | 2024-12-31 | $114,701,000 | reported | |
| FY 2023 | 2023-12-31 | $0 | reported | |
| FY 2022 | 2022-12-31 | $0 | reported |
Segments
Products
LineFY2025ShareChange
Revenue from contracts with collaborators$48.47M100%+101.8%
Revenue from sale of licenses$0.00—−100.0%
Total$48.47M
Pharmaceutical preparations
Gossamer Bio, Inc. is the 129th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
OCULOcular Therapeutix, Inc$52.0M18.5%511.9%$1.4BLXRXLexicon Pharmaceuticals, Inc.$49.8M729.9%101.1%$812.6M
GOSSGossamer Bio, Inc. (this company)$48.5M57.7%351.5%$68.0M
PTGXProtagonist Therapeutics, Inc$46.0M89.4%282.8%$8.8BSEPNSepterna, Inc.$46.0M4,174.5%106.4%$2.0BAQSTAquestive Therapeutics, Inc.$44.5M22.6%188.1%$448.7MCPIXCumberland Pharmaceuticals Inc$44.5M17.6%6.4%$98.5MINBPIntegrated Biopharma Inc$43.9M19.3%6.5%$9.1MXLOXilio Therapeutics, Inc.$43.8M589.9%80.1%$58.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Gossamer Bio, Inc. · CIK 1728117 · Engraved from SEC EDGAR